Murine and human epidermal growth factor receptors (EGFRs) bind human EGF (hEGF),mouse EGF (mEGF), and human transforming growth factor
(hTGF-
) with high affinity despite thesignificant differences in the amino acid sequences of the ligands and the receptors. In contrast, the chickenEGFR can discriminate between mEGF (and hEGF) and hTGF-
and binds the EGFs with approximately100-fold lower affinity. The regions responsible for this poor binding are known to be Arg
45 in hEGF andthe L2 domain in the chicken EGFR. In this study we have produced a truncated form of the hEGFRectodomain comprising residues 1-501 (sEGFR501), which, unlike the full-length hEGFR ectodomain(residues 1-621, sEGFR621), binds hEGF and hTGF-
with high affinity (
KD = 13-21 and 35-40 nM,respectively). sEGFR501 was a competitive inhibitor of EGF-stimulated mitogenesis, being almost 10-fold more effective than the full-length EGFR ectodomain and three times more potent than the neutralizinganti-EGFR monoclonal antibody Mab528. Analytical ultracentrifugation showed that the primary EGFbinding sites on sEGFR501 were saturated at an equimolar ratio of ligand and receptor, leading to theformation of a 2:2 EGF:sEGFR501 dimer complex. We have used sEGFR501 to generate three mutantswith single position substitutions at Glu
367, Gly
441, or Glu
472 to Lys, the residue found in the correspondingpositions in the chicken EGFR. All three mutants bound hTGF-
and were recognized by Mab528.However, mutant Gly
441Lys showed markedly reduced binding to hEGF, implicating Gly
441, in the L2domain, as part of the binding site that recognizes Arg
45 of hEGF.